The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients

Lu Sun; Wenjin Yin; Ziping Wu; Yaohui Wang; Jinsong Lu

추천

검색

자료유형: 학술저널

저자정보: Lu Sun (Shanghai Jiaotong University) Wenjin Yin (Shanghai Jiaotong University) Ziping Wu (Shanghai Jiaotong University) Yaohui Wang (Shanghai Jiaotong University) Jinsong Lu (Shanghai Jiaotong University)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.23 No.5

발행연도: 2020.1

수록면: 509 - 520 (12page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Gamma-glutamyl transferase (GGT) has been reported as being involved in tumor progression. Previous studies documented a potential relationship between serum GGT level and survival outcome in several types of human malignancies. However, the association between serum GGT levels and response to neoadjuvant chemotherapy (NAC) has not yet been reported. The present study aimed to evaluate the association between pre-therapeutic serum GGT level and the efficacy, long-term survival, and adverse reactions of NAC and to investigate its role in predicting NAC sensitivity in patients with breast cancer. Methods: A total of 129 patients were recruited and stratified into 2 groups according to serum GGT level (< 29 U/L and ≥ 29 U/L). The association between pre-therapeutic serum GGT levels and clinicopathological parameters was examined. The correlation between pre-therapeutic serum GGT levels and pathological complete response (pCR) was analyzed using univariate and multivariate logistic regression. Survival analyses of relapse-free survival (RFS) and disease-free survival (DFS) were performed. Pearson's χ2 test and multivariate logistic regression model were used to analyze the correlation between pre-therapeutic serum GGT levels and adverse reactions. Results: Pre-therapeutic serum GGT levels were associated with pCR among breast cancer patients treated with NAC. Multivariate analysis showed that low-level GGT significantly increased pCR rate. Patients in the high-level GGT group had poorer survival than those in the low-level GGT group. Subgroup analysis demonstrated that serum GGT level was potentially related to RFS and DFS in the hormone receptor-positive group. Low levels of GGT are significantly associated with a higher incidence of neutropenia. Conclusion: Pre-therapeutic serum GGT level is an independent and novel biomarker for predicting the efficiency, prognosis, and adverse reactions to NAC in breast cancer patients. Patients with low pre-therapeutic serum GGT levels are more likely to have higher pCR rates, better RFS and DFS, and higher hematologic toxicity.

#Breast cancer #Gamma-glutamyltransferase #Neoadjuvant therapy #Chemotherapy #Prognosis

참고문헌 (29)

참고문헌 신청

Cortazar P / 2014 / Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis / Lancet 384:164~172

Chen Y / 2016 / Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients : a retrospective study / BMC Cancer 16:320

Lim JS / 2004 / Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress / Free Radic Biol Med 37:1018~1023

Hanigan MH / 2014 / Gamma-glutamyl transpeptidase : redox regulation and drug resistance / Adv Cancer Res 122:103~141

Strasak AM / 2008 / Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women / Int J Cancer 123:1902~1906

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!